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Abstract 
Background: Oxidative stress is responsible for some alterations in the chemical structure and, consequently, in 
the function of proteins, lipids, and DNA. Recent studies have linked oxidative stress to cancers, particularly thyroid 
cancer, but the mechanisms remain unclear. Here, we further characterize the role of oxidative stress in thyroid cancer 
by analyzing the expression of two selenium antioxidant molecules, glutathione peroxidase (GPx1) and thioredoxin 
reductase (TrxR1) in thyroid cancer cells.
Methods: Samples of both healthy thyroid tissue and thyroid tumor were taken for analysis after total thyroidectomy. 
The expression of GPx1 and TrxR1 was revealed by Western blot analysis and quantified by densitometric analy-
ses, while the evaluation of free radicals was performed by Electron Paramagnetic Resonance (EPR)-spin trapping 
technique.
Results: Our results show a decrease in the expression of GPx1 and TrxR1 (− 45.7 and − 43.2% respectively, p < 0.01) 
in the thyroid cancer cells compared to the healthy cells. In addition, the EPR technique shows an increase of free 
radicals in tumor tissue, significantly higher than that found in healthy thyroid tissue (+ 116.3%, p < 0.01).
Conclusions: Our findings underscore the relationship between thyroid cancer and oxidative stress, showing the 
imbalance of the oxidant/antioxidant system in thyroid cancer tissue. These results suggest that either the inability to 
produce adequate antioxidant defense or an increased consumption of antioxidants, due to the hyper-production of 
free radicals, may play a crucial role in thyroid cancer.
Keywords: Oxidative stress, Thyroid cancer, Glutathione peroxidase (GPx1), Thioredoxin reductases (TrxR1), Selenium 
enzymes
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Background
The overproduction of free radicals and the consequent 
increase in oxidative stress lead to irreversible cellu-
lar damage, frequently associated with diseases such 
as atherosclerosis, hypertension, diabetic nephropa-
thy, pulmonary fibrosis, Alzheimer’s disease, and in 
particular, cancer [1–10]. In thyroid cancer specifically, 
chemical modifications of DNA structure that are typi-
cally induced by oxidative stress, such as the presence of 
8-oxo-2′-deoxyguanosine, have been found by microar-
ray and immunohistochemistry analyses [11]. Moreover, 
high concentrations of glutathione peroxidase (an anti-
oxidant enzyme) and malondialdehyde (a product of lipid 
peroxidation) were found in the blood of patients affected 
by thyroid cancer [12]. We recently described an increase 
of oxidative stress in the blood of patients affected by 
thyroid cancer, detected by electronic proton resonance 
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measurements, a refined technique to study qualitatively 
and quantitatively the oxidizing species in human blood. 
In addition, another interesting finding of our study was 
the meaningful decrease of oxidative stress observed in 
all subjects after thyroidectomy [13].
Our previous studies suggest the involvement of oxi-
dative stress in the pathogenesis of thyroid cancer, but 
the mechanisms remain unclear. Cells regulate the redox 
state by balancing the generation of free radicals with 
their elimination by antioxidant systems [14]. A wide array 
of vitamins, minerals, and other minor compounds are 
involved these antioxidant systems [15]. In this study, we 
focused our attention on selenoproteins, a class of pro-
teins containing selenium that seems to play a critical role 
in the balance of the oxidant/antioxidant systems. In fact, 
some of them, e.g. glutathione peroxidases (GPxs) [16] 
and thioredoxin reductases (TrxRs) [17] play a large role in 
antioxidant defense and in the maintenance of the intercel-
lular reducing conditions. Since increased oxidative stress 
has been implicated in thyroid cancer, we hypothesized 
that the impairment of the expression of selenoproteins 
may be a key factor towards clarifying the relationship 
between thyroid cancer and oxidative stress. This study 
elucidates the mechanism involved in the antioxidant/oxi-
dant system in thyroid cancer, focusing the attention on 
the role played by selenoproteins GPx1 and TrxR1.
Methods
Patient recruitment
The study population was recruited in 2014 at the 
Department of Surgical Sciences of the Umberto I Hos-
pital of Rome. Patients were between 24 and 68  years 
of age, with thyroid nodules classified as indeterminate 
(TIR3B), suspicious for malignant (TIR4) or malignant 
(TIR5) after cytologic examination, according to the 
“Italian Consensus for the classification and reporting 
of thyroid cytology, 2014” [18]. The Fine Needle Aspira-
tion (FNA) to obtain samples for the cytological evalu-
ation was performed only on thyroid nodules ≥  1  cm 
with suspicious ultrasound (US) features, according to 
“Sonographic and Clinical Features of Thyroid Nodules 
and Recommendations for FNA” of the American Thy-
roid Association (ATA) [19]. Considering the cytological 
results (Table 1), all patients were candidates for thyroid 
surgery, according to the ATA 2009, the only one known 
at the time of the recruitment.
Surgical treatment
Surgical treatment was planned taking into account the 
cytological diagnosis, lymph node involvement and the 
size of the suspicious nodule (both evaluated through US 
of the neck), age of patients, and a history of prior head 
and neck irradiation. In cases with a cytologic diagnosis 
Table 1 Classification of the patients, taking into account the preoperative cytological diagnosis (FNA diagnosis), the 
post-operative diagnosis (histological diagnosis, variant and tumor size), the surgical approach, and the staging (accord-
ing to the AJCC Cancer Staging Manual 2009, 7th edition)
TT indicates total thyroidectomy, while Roman numerals indicate the location of lymph nodes in the neck
Case FNA diagnosis Histological diagnosis Variant Histological size (cm) Surgical approach Staging
1 TIR4 Papillary Classical 0.7 TT pT1a
2 TIR4 Papillary Classical 0.6–0.4 TT and level VI pT1am pN0
3 TIR3B Papillary Follicular 1.5 TT pT1b
4 TIR5 Papillary Classical 0.8 TT and level VI pT1a pN0
5 TIR4 Papillary Classical 1.4 TT and level VI pT1b pN0
6 TIR3B Papillary Follicular 1.2 TT pT1b
7 TIR3B Papillary Follicular 1.5 TT pT1b
8 TIR5 Papillary Classical 1.7 TT and level VI pT1b pN1a
9 TIR4 Papillary Classical 2.5–1.5 TT and level VI pT2m pN1a
10 TIR4 Papillary Classical 1.5–0.9 TT and level VI pT1bm pN1a
11 TIR4 Papillary Classical 0.8 TT and level VI pT1a pN0
12 TIR4 Papillary Classical 1.8 TT and level VI pT1b pN1a
13 TIR4 Papillary Classical 2.8 TT and level VI pT2 pN1a
14 TIR5 Papillary Classical 1.4 TT and level VI pT1b pN1a
15 TIR4 Papillary Classical 1.6 TT and levels II, III, IV, VI pT1b pN1a
16 TIR3B Papillary Follicular 1.1 TT pT1b
17 TIR5 Papillary Classical 2.1 TT and levels II, III, IV, VI pT2 pN1b
18 TIR5 Papillary Classical 0.7 TT and level VI pT1a pN0
19 TIR5 Papillary Classical 2.8–1.2 TT and levels II, III, IV, VI pT2m pN1b
20 TIR5 Papillary Classical 1.3 TT and levels II, III, IV, VI pT1a pN1b
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of malignancy (TIR4, TIR5), the patients underwent total 
thyroidectomy, according to ATA 2009 (recommenda-
tion 26). Thyroid lobectomy alone may be sufficient treat-
ment for small (< 1 cm), low-risk, unifocal, intrathyroidal 
papillary carcinomas in the absence of prior head and 
neck irradiation or radiologically or clinically involved 
cervical nodal metastases, as suggested by ATA 2009. 
However, none of our TIR4/TIR5 patients were can-
didates for lobectomy. In fact, as previously described, 
only patients with suspicious nodules ≥ 1 cm underwent 
FNA and were included in the study. Table 1 reports the 
histological size of the tumor, measured “ex vivo” after 
thyroidectomy, which is often different from the pre-
operative US measurements. Patients with clinically 
involved central compartment (level VI) lymph nodes 
underwent therapeutic central neck dissection along 
with total thyroidectomy (Table 1, cases 2, 4, 5, 8, 9, 10, 
11, 12, 13, 14, 15, 17, 18, 19, 20). Patients with suspicion 
for lateral lymph node disease (compartments II–IV) on 
preoperative US or intraoperative exam also underwent 
lateral neck dissection (Table 1, cases: 15, 17, 19, 20; ATA 
2009, recommendation 27). Patients 3, 6, 7 and 16, with 
indeterminate nodules (TIR3B), preferred to undergo 
total thyroidectomy, to avoid the possibility of requiring 
a future surgery on the contralateral lobe as provided by 
ATA 2009 (recommendation 25b). Informed consent was 
obtained from all participants. The criteria of exclusion 
from the study were the presence of debilitating diseases 
(i.e. advanced stage diabetes, immunological diseases or 
hematologic disorders), lack of informed consent, and/or 
lack of authorization form for the processing of personal 
data. All subjects recruited for the study underwent the 
following: electrocardiogram, chest X-ray, indirect laryn-
goscopy, and whole blood sampling. The following blood 
tests were obtained for each patient: hemochromocyto-
metric analysis, routine chemistry tests, TSH, FT3, FT4, 
calcitonin, thyroglobulin, anti-thyroperoxidase antibody 
(TPOAb), and anti-thyroglobulin antibody (TgAb). In 
order to obtain a comparison between healthy thyroid 
tissue and cancer tissue in each individual patient, we 
selected only those patients (candidates for total thyroid-
ectomy) with unilateral suspicious cytological nodules.
Chemicals and instruments
Antibodies were obtained from the following sources: 
polyclonal anti-glutathione peroxidase (GPx1) and poly-
clonal anti-thioredoxin reductase 1 (TrxR1) and RIPA 
buffer from Sigma–Aldrich (St Louis, MO, USA), mono-
clonal anti-actin from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA), peroxidase-conjugated goat anti-mouse 
and peroxidase-conjugated rabbit anti-goat from Amer-
sham (Arlington Heights, IL, USA). Nitrocellulose paper 
was obtained from Shleicher & Schuell Bioscience Inc. 
(Dassel, Germany). Enhanced chemiluminescent kit (ECL 
kit) and BCA Protein Assay Kit were purchased from 
Pierce (Rockford, IL, USA). The densitometric analyses 
of selenium protein were performed using the GS-900 
densitometer (Bio-Rad) and the “Image J” Software. Spin 
trap 1-hydroxy-3-carboxy-pyrrolidine (CPH), 3-carboxy-
proxyl radical (CP·) was purchased from ENZO Biochem 
(Laufelfingen, Switzerland).
Sampling the thyroid tissue for selenoprotein analysis
A complete histological exam of the thyroid gland was 
performed after thyroidectomy to characterize the 
lesions and to obtain the definitive histological clas-
sification (Table  1). All patients in which the definitive 
histological exam revealed, in the uninvolved lobe, an 
incidental cancer lesion or signs of inflammation or other 
types of disease were excluded from this study. A sam-
ple of tissue containing the thyroid cancer and a sample 
of the contralateral lobe were taken from the gland at the 
time of surgery and conserved at − 80 °C for future anal-
ysis and measurement of selenoproteins, GPx1 and TrxR.
Preparation of thyroid gland proteins extract
To obtain a protein lysate on which to detect GPx1 and 
TrxR1 proteins, each thyroid sample was suspended 
in 200  µL of phosphate buffer saline and solubilized by 
incubation for 10  min at 0  °C with an equal volume of 
100  mM Tris–HCl (pH 7.5), 0.6  M NaCl, 4% (w/v) Tri-
ton X-100, 4% (v/v) sodium deoxycholate, 0.4 mM PMSF, 
1  µg/mL leupeptin and 1  µg/mL aprotinin (4× RIPA 
buffer). The solution was then diluted once with Phos-
phate Buffer Saline and adjusted to a final volume of 1 mL 
with 1× RIPA buffer. After centrifugation at 16,000g for 
30 min at 4  °C, the supernatant, constituted by the thy-
roid tissue lysate, was collected for the western blot or 
EPR analyses. The protein content in thyroid tissue lysate 
was detected using the Pierce BCA Protein Assay Kit, to 
obtain an equal amount of protein in each sample.
Western blot analysis
Samples prepared for Western Blot analysis were solubi-
lized in 4× loading buffer, boiled for 5 min, and resolved 
by Sodium Dodecyl Sulphate–PolyAcrylamide Gel Elec-
trophoresis (SDS–PAGE). Proteins were transferred to 
nitrocellulose paper at 35 V overnight. Blots were washed 
with TBS containing 0.05% Tween 20 (TTBS) and 
blocked with 3% bovine serum albumin in TTBS for 2 h. 
Washed nitrocellulose filters were incubated overnight 
at 4 °C with the anti-GPX1 or anti-TrxR1 antibody. After 
extensive washes in TTBS, the immunoreactive bands 
were detected by chemiluminescence coupled to peroxi-
dase activity, according to the manufacturer’s specifica-
tions (ECL kit; Pierce).
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Densitometric analysis of the selenoproteins GPx1 
and TrxR1
In order to measure GPx1 and TrxR1 expression levels, 
the intensities of specific bands, corresponding to the 
selenoproteins of interest, were measured. The densi-
tometric analysis of the blots was done using the Image 
J Software [20]. In brief, the blot images were imported 
into the software and the contrast was adjusted such 
that the bands were clearly visible on the blot image. The 
area around each band was selected and the background 
intensity was subtracted from the blot image. The inten-
sities of the selected bands were then expressed as a 
numeric value (arbitrary unit, a.u.) that could be used for 
carrying out further statistical analyses.
Electron paramagnetic resonance (EPR)‑spin probing 
analysis of thyroid tissue
Free radicals are highly reactive species with half-lives 
usually less than 1 ms and are hardly detectable by direct 
EPR technique alone. This limitation is overcome by 
combining the EPR technique with spin probing. In brief, 
an organic compound (in our case 1-hydroxy-3-carboxy-
pyrrolidine (CPH), capable of reacting with the radical 
species present, is added into the study system. The reac-
tion product is a nitroxide radical (CP·), which is much 
more stable and therefore easily detectable by EPR tech-
nique [21]. Spectra were measured on a Bruker ECS 106 
spectrometer equipped with a variable-temperature unit 
(ER4111VT). Samples were drawn up into a gas-permea-
ble Teflon tube with 0.81-mm internal diameter and 0.05-
mm wall thickness (Zeuss Industrial Products, Raritan, 
NJ, USA). The Teflon tube was folded four times, inserted 
into an open (air) quartz tube, and fixed to the EPR cavity 
(4108 TMH). The temperature was 37 °C. All ESR spec-
tra were corrected for baseline drift by a linear function 
and double integrated and simulated using the software 
supplied by Bruker (ESP 1600 data system). Spectrometer 
conditions common to all spectra were modulation fre-
quency, 100 kHz; microwave frequency, 9.4 GHz; micro-
wave power, 20 mW.
Statistical analysis
All data were expressed as the mean (± standard devia-
tion) of at least three measurements and analyzed with 
the Student’s t test or Two-Way ANOVA with Bonferroni 
post-test using the statistical software Graph Pad Prism 
4.0 (GraphPad Software, Inc., CA, USA).
Results
Surgical treatment and outcome
All patients underwent total thyroidectomy. Therapeu-
tic lymph node dissection was performed when cervi-
cal lymph node metastases were suspected or shown 
preoperatively or intraoperatively by the clinical or radi-
ological examination. For all patients, the recovery was 
uneventful, and discharge was on the third postoperative 
day. No significant decrease was detected in blood cal-
cium levels after surgery.
Thyroid histological analysis and staging
Histology of the thyroid tissue demonstrated papillary 
thyroid cancer in all patients: 16 patients with classical 
variant (4 with multifocal cancer), and 4 patients with fol-
licular variant. Cervical neck dissection was performed 
on 15 patients with clinically involved lymph nodes, 
and lymph node metastases were found in 10 patients. 
Table 1 summarizes the preoperative cytological diagno-
sis, the post-operative histological classification, the sur-
gical approach, and the staging.
Evaluation of GPx1 and TrxR1 expression in thyroid tissue
The overall protein composition of each patient’s thy-
roid tissue was determined by SDS-PAGE, and the pro-
tein content was verified by a specific protein staining 
(data not shown). The expression of GPx1 and TrxR1 was 
detected by the appropriate antibodies, able to identify 
only these two proteins in the thyroid protein lysate. Fig-
ures 1 and 2 show the Western blotting results referred 
to GPx1 and TrxR1, respectively. For each patient, two 
samples were tested for the presence of GPx1 and TrxR1: 
one sample from the healthy thyroid tissue and one sam-
ple from the cancer tissue. As demonstrated in Fig.  1, 
the intensity of the band detected by the anti-GPx1 anti-
body in thyroid cancer tissue was lower for all patients 
than those detected in healthy tissue. Similar results 
were obtained using the anti-TrxR1 antibody. In fact, all 
patients showed a decrease of the TrxR1 expression in 
cancer tissue compared to the healthy tissue. These find-
ings support the hypothesis that an impairment in the 
ability of the antioxidant system to counteract oxidative 
stress may be implicated in thyroid cancer.
Densitometric analyses of antioxidant enzyme expression
Western blot analyses showed a decrease in GPx1 and 
TrxR1 expression in thyroid cancer, without a real quan-
tification of the difference. In order to better quantify 
our results, we performed a densitometric analyses of 
the bands representing GPx1 and TrxR1 in the western 
blot. To be sure that these results were not due to a dif-
ferent protein content between the two types of tissue, 
we decided to normalize our results with respect to actin, 
a ubiquitous protein present in all eukaryotic cells. Tak-
ing all patients together, the densitometric analysis of 
the GPx1 expression showed a significant lower mean 
concentration in cancer tissue, compared to healthy tis-
sue. GPx1 expression in cancer tissue (red line, Fig.  1a) 
Page 5 of 8Metere et al. Cancer Cell Int  (2018) 18:7 
was 44.4  ±  2.8% less than the average values detected 
in healthy tissue (black line, Fig.  1a) (p  <  0.001, range 
+ 27 to − 74%). Furthermore, the difference of the GPx1 
expression between healthy and cancer tissue, measured 
for each patient, was statistically significant for 16 of 
the 20 patients studied (Fig.  1b). The average TrxR1 
expression was also decreased in tumor tissue when 
compared to healthy tissue, a difference of 49  ±  1.2% 
Fig. 1 a Densitometric analysis of Western blotting reveals a meaningful decrease of the GPx expression (− 44.4 ± 2.8%, p < 0.01) in cancer (red 
line) with respect to the healthy thyroid tissue (black line). No differences were found between cancer and healthy tissue for the actin expression 
(data not shown). b Western blotting analysis of GPx1 and actin expression in cancer (C) and healthy (H) thyroid tissue. The numbers below identify 
the patient (see Table 1). NS not significant, *p < 0.01)
Fig. 2 a Densitometric analysis of Western blotting shows also in this case a significant decrease of TrxR1 expression (− 49 ± 1.2%, p < 0.01) in 
cancer (red line) with respect to the healthy thyroid tissue (black line). b Western blotting analysis of TrxR1 and actin in cancer (C) and healthy (H) 
thyroid tissue shows a general reduction of TrxR1 in cancer (C). The numbers below identify the patient (see Table 1). NS not significant, *p < 0.01
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(p < 0.001, range − 3 to − 63%). Moreover, the mean val-
ues of the peaks obtained by the densitometric analysis 
of TrxR1 expression in thyroid cancer tissue (red line, 
Fig. 2a) were significantly lower than those measured in 
healthy tissue (black line, Fig.  2a), 98,965 ±  103,326 vs. 
1,963,000  ±  91,242 a.u., p  <  0.0001, respectively. Com-
paring individual patients’ tumor tissue to their own 
healthy tissue, the difference of TrxR1 expression was 
statistically significant for everyone (Fig. 2b).
Free radical production in thyroid cancer detected 
by EPR‑spin probing
As previously described [20] EPR-spin technique has 
proved very useful in being able to detect free radicals 
within some human tissues. Using this technique, we 
detected a significant increase in the production of free 
radicals in all of the thyroid tumor tissue samples, com-
pared to the healthy tissue of the same patient. In par-
ticular, the mean value detected in the cancer tissues was 
12.07 ±  0.97 a.u., while that detected in healthy tissues 
was 5.58 ± 0.89 a.u. p < 0.01). These data indicate, une-
quivocally, that the process of carcinogenesis is closely 
related to the physiological mechanisms responsible for 
the balance between oxidants and antioxidants species 
(Fig. 3).
Discussion
It has been suggested that up to 100 selenoproteins may 
exist in mammalian systems [22], of which up to 30 
have been identified by 75Se labeling in  vivo [23]. GPx 
enzymes, known as classical GPx1 (the first selenopro-
tein identified), gastrointestinal GPx2, plasma GPx3 and 
phospholipid hydroperoxide GPx4, represent the major 
classes of functionally important selenoproteins. GPx1 
is ubiquitously expressed in many tissues and is pre-
sent in the cell cytosol and in the mitochondria, where 
it functions as an antioxidant by directly reducing  H2O2 
to water and lipid hydroperoxides to their correspond-
ing alcohol [24]. It may also act as a storage vehicle for 
selenium, containing 4 selenocysteine residues in a tetra-
meric structure [25, 26].
Another interesting selenoprotein is TrxR, an enzyme 
that catalyzes the NADPH-dependent reduction of 
thioredoxin and therefore plays a regulatory role in its 
metabolic activity. In fact, thioredoxins are proteins char-
acterized at the level of their amino acid sequence by 
the presence of two cysteines that act as antioxidants by 
facilitating the reduction of other oxidized proteins by 
cysteine thiol-disulfide exchange [27]. TrxR is the only 
enzyme known to catalyze the reduction of thioredoxin. 
In brief, the electrons are taken from NADPH via TrxR 
and transferred to the active site of thioredoxin, which 
goes on to reduce protein disulfides or other substrates.
Moreover, thioredoxin stimulates proliferation of nor-
mal and tumor cells, and is present in high concentra-
tions in tumor cells [28], so an impairment of the TrxR 
activity may be involved in some forms of cancer. In fact, 
the expression levels of the cytosolic isoform Trx1 and 
TrxR1 are linked to tumor aggressiveness, chemo-resist-
ance and to resistance to apoptosis [29–31]. As previ-
ously described, numerous types of cancer cells have high 
levels of free radicals [32–34]. Cancer cells with elevated 
free radicals production frequently present a compro-
mised antioxidant defense system, which will give rise to 
an overproduction of free radicals and the consequent 
increase in oxidative stress, resulting in the impairment 
of some physiological activities such as cellular metabo-
lism, cellular growth and mitosis [35].
The coupling of the EPR-spin trapping probing tech-
nique with CPH can be used to assess the redox pro-oxi-
dant state of cells, both in physiological and pathological 
conditions. The EPR technique is able to detect the oxi-
dizing species produced and is extremely sensitive to the 
changes in the redox state [36, 37]. A refined technique 
like EPR gave us the opportunity to detect the overpro-
duction of free radicals in cancer cell lysate compared to 
those detected in healthy thyroid tissue.
In this preliminary study, we show that oxidative stress 
in thyroid cancer is increased compared to that detected 
in healthy tissues, as suggested by the statistically higher 
CP· concentration. Moreover, the decrease in antioxi-
dant enzymes GPx1 and TrxR1 in cancer tissue indicates 
that the antioxidant system in cancer cells is unable to 
adequately counteract the effects of the free radicals. All 
patients affected by thyroid cancer showed a reduced 
expression of these two antioxidants enzymes in tumor 
tissue, compared to those detected in healthy tissue.
Several different mechanisms are involved in the over-
production of free radicals, resulting in the augmented 
Fig. 3 EPR measurement of reactive oxygen species in thyroid tissue. 
The red line shows the concentration of CP· in cancer tissue (C), while 
the black line shows the concentration of CP· detected in healthy 
thyroid tissue (H). The statistical analysis was significant for all patients
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oxidative stress that afflicts thyroid cancer. As a result, 
the oxidative stress can only be partially explained by 
taking into account the defective antioxidant system 
of seleno-enzymes GPx1 and TrxR1. There are many 
sophisticated changes in the biology of cancer cells, so to 
consider only these enzymes as responsible for thyroid 
cancer is reductive, although our study shows that a con-
tribution of GPxr1 and TrxR1 is likely possible. There are 
numerous variabilities that we were unable to account for 
in this small pilot study, such as the size of tumor, lymph 
node involvement, the multifocality of cancer, or the his-
totype of cancer. Moreover, our small population of sub-
jects limited our statistical power, though, by comparing 
healthy vs. tumor samples within the same patient, we 
attempted to control for many between-patient variables.
Conclusions
Our findings show, unequivocally, the involvement of 
oxidative stress in thyroid cancer by demonstrating the 
imbalance of the oxidant/antioxidant system directly in 
thyroid cancer tissue. Further studies on the distribution 
of antioxidant molecules in cancer cells and the charac-
terization of free radical intracellular pathways will be 
the critical steps in defining the role of the oxidant/anti-
oxidant system in the thyroid cancer. The data obtained 
in our pilot study push us to further explore the role of 
seleno-enzymes in cancer. Currently, we are increas-
ing our sample size and performing metabolic studies, 
with the use of magnetic resonance, to detect changes in 
metabolites of thyroid cancer cells.
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